CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously

Biotech thinks its PPAR delta agonist will prove much more potent than Genfit’s elafibranor from the same class and will offer a better tolerability profile than Intercept’s OCA.

Sujal Shah of CymaBay Pharmaceuticals.
CymaBay CEO Sujal Shah

CymaBay Therapeutics Inc. is taking a similar route to market with its PPAR delta agonist seladelpar as Intercept Pharmaceuticals Inc. took with obeticholic acid (OCA) – and with a drug that is the same class as Genfit SA, another market leader. CymaBay hopes to obtain approval first in primary biliary cholangitis (PBC), as Intercept did, and then move on to non-alcoholic steatohepatitis (NASH).

Seladelpar is a selective agonist of peroxisome proliferator-activated receptor delta (PPAR delta), while Genfit’s elafibranor, in Phase III in NASH...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category